Breaking the CD Iceberg with novel tTg detection kit

Tissue Transglutaminase (tTg) has been identified as the major target antigen in endomysium in 1997 by Dieterich and Schuppan et.al. Over the last 10 years, gliadin testing has been replaced by tTg testing thus, celiac disease (CD) diagnosis has risen to a sensitivity and specificity level unknown before. Even after this main serological discovery, a vast majority of celiac patients still remain undetected (ratio of known to unknown CDis 1 to 7) and there’s a mean delay on a CD diagnosis of 5 to 11 years. Several theories about the “iceberg model” were published, and studies have shown that CDalso exists in different underestimated forms referred to as potential, latent and silent CD. Meta-analyses of current studies indicate that celiac disease affects 1% of the population worldwide. Risk groups (like DM type 1 and osteoporosis) have an even higher prevalence (from 1:20 to 1:7).
In 2002, with this question in mind Aesku started researching on several scientific discoveries. The basic idea behind the research was to observe how tTg and Gliadin, as a component of our diet, could induce toxicity leading to an autoimmune phenomenon.
When looking at the way Gliadin is digested by our enzymes, some peptides of gliadin are resistant to further degradation.These resistant gliadin peptides are an ideal target for tTg due to their high percentage of glutamine residues (35%). These residues can be deamidated or crosslinked by tTg on a ratio of 1:4.
After the “in-vitro” studies,it was found with an “in-vivo” study confirmation, that all these modifications (crosslinking and deamidation) also occur “in-vivo” and complexes of tTg and gliadin can be found in duodenal mucosa.
This was the birth of the AESKULISA® tTg New Generation!

Aeskulisa® tTg New generation: LOOK Closer to the truth!

The physiological processes which are mimicked by the antigens are used for the AESKULISA® tTg New Generation:
In Aesku’s special production process tTg and gliadin peptides are reacting under special conditions comparable to the “in-vivo” environment, in order to encourage both reactions: crosslinking and deamidation.
The whole reaction ensures the formation of the neo-epitope as it is encountered by the immune system “in-vivo”. These crosslinked and deaminated antigens (tTg / deamidated gliadin peptides) are then further purified and coated under special conditions to the microtiter plate.
Due to its special formulation, the AESKULISA® tTg New Generation is able to detect 3 different types of antibodies:

  • Antibodies to tTG
  • Antibodies to deamidated gliadin peptides
  • Antobodies to neo-epitope formed by crosslinking of tTg and DGP

THE AESKULISA PRODUCT LINE : INNOVATIVE DIAGNOSTICS EASY TO USE


AESKULISA tests are already established as an ideal partner for laboratory automation systems as all kits are based on the same workflow :

  • One protocol
  • One sample dilution
  • One buffer system
  • One cut-off
  • One standard curve

The user benefits from :
Maximum specificity and sensitivity by


  • Using recombinant antigens
  • Breakaway microwells
  • Colour-coded vials and reagents
  • Concentration-dependent colour coding of calibrations
  • Short incubation time